Lobular carcinoma in situ is not considered cancer. Despite the word “carcinoma” in its name, LCIS is classified as a high-risk marker, meaning it signals an increased chance of developing invasive breast cancer in the future rather than being a cancer that needs immediate treatment. The American Joint Committee on Cancer removed LCIS from its staging system entirely in 2018, no longer categorizing it as even a “stage 0” tumor.
Why the Name Is Misleading
The term “lobular carcinoma in situ” was coined decades ago when pathologists first identified these abnormal cells in the milk-producing lobules of the breast. “In situ” means “in place,” describing cells that look unusual under a microscope but haven’t broken through the walls of the lobule to invade surrounding tissue. At the time, it was grouped alongside ductal carcinoma in situ (DCIS), which is still treated as a pre-cancerous condition. Over the years, research clarified that classic LCIS behaves quite differently. It’s managed as a benign finding that doesn’t require complete surgical removal or even clear margins around the biopsy site.
What makes LCIS biologically distinct is a protein called E-cadherin, which acts like glue holding normal breast cells together. In LCIS, cells lose this protein almost completely from the earliest stage. This loss is how pathologists confirm they’re looking at a lobular lesion rather than a ductal one. It’s a defining feature, not just an incidental finding.
What LCIS Actually Means for Your Risk
An LCIS diagnosis raises your lifetime risk of developing invasive breast cancer to roughly 30 to 40 percent. That’s substantially higher than the average woman’s lifetime risk of about 13 percent, but it also means the majority of women with LCIS will never develop invasive cancer.
One important detail: the risk applies to both breasts, not just the one where LCIS was found. In a study of over 5,500 women with LCIS, about 8 percent went on to develop invasive breast cancer. Of those, 4.5 percent developed cancer in the same breast and 3.6 percent in the opposite breast. This roughly even split reinforces the idea that LCIS is a whole-breast (and whole-body) risk factor rather than a localized problem that needs to be cut out.
Classic LCIS vs. Pleomorphic LCIS
Not all LCIS is the same. Classic LCIS, the most common type, is the version that’s managed conservatively. Pleomorphic LCIS is a rarer variant where the abnormal cells look more aggressive under a microscope. Pleomorphic lobular cancers, when they do become invasive, tend to be diagnosed at a more advanced stage, with larger tumors and more frequent spread to lymph nodes. About 20 percent of patients with invasive pleomorphic lobular cancer have multiple lymph node metastases at diagnosis, compared to 11 percent for the classic invasive form.
If your biopsy shows pleomorphic LCIS, your care team will likely take a more proactive approach, potentially including surgical excision. The distinction matters, so it’s worth confirming which type your pathology report describes.
How LCIS Is Managed
Because classic LCIS is treated as a risk factor rather than a cancer, the standard approach is close surveillance rather than surgery. Current guidelines recommend a clinical breast exam every 6 to 12 months, an annual screening mammogram (preferably with tomosynthesis, sometimes called 3D mammography), and an annual breast MRI. This combination catches changes early if invasive cancer does develop.
When LCIS is found on a core needle biopsy and the imaging findings match what the pathologist sees (called radiologic-pathologic concordance), observation alone has become the standard of care. Studies comparing surgical excision to monitoring in these cases found low rates of hidden cancer at the biopsy site, supporting the watch-and-wait approach. Surgery is typically reserved for cases where the imaging doesn’t fully explain the biopsy findings or where other high-risk features are present.
Risk Reduction Options
Beyond surveillance, medications can meaningfully lower your future cancer risk. Tamoxifen reduces the risk of invasive breast cancer by about 50 percent in high-risk women, while raloxifene reduces it by about 38 percent. Both drugs work by blocking the effects of estrogen on breast tissue. They come with their own side effects and aren’t right for everyone, but for women with LCIS who want to actively lower their odds, these are well-studied options.
Some women with LCIS and additional risk factors, such as a strong family history or genetic mutations, may consider preventive mastectomy. This is far less common and is a deeply personal decision. For most women with classic LCIS and no other major risk factors, the combination of regular screening and possible risk-reducing medication provides a solid safety net.
What Your Pathology Report Means in Practice
If you’ve been told you have LCIS, the most important thing to understand is that nothing in your breast requires urgent treatment right now. Your body has given you an early warning signal. The cells found in your biopsy are not invading surrounding tissue, are not spreading, and may never become cancer. What they do tell you is that your breast tissue carries a higher-than-average likelihood of developing invasive cancer over the coming decades, in either breast.
That knowledge is genuinely useful. It puts you in a position to screen more aggressively, catch problems earlier, and consider preventive strategies that can cut your risk in half. Women whose LCIS is caught and monitored have excellent long-term outcomes precisely because they know what to watch for.